Scarica l'app Stockscreener
448.28
0.24%
-1.09
Dopo l'orario di chiusura:
445.00
-3.28
-0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$449.37
Aprire:
$446.8
Volume 24 ore:
1.67M
Relative Volume:
0.79
Capitalizzazione di mercato:
$166.59B
Reddito:
$45.20B
Utile/perdita netta:
$6.87B
Rapporto P/E:
24.65
EPS:
18.1888
Flusso di cassa netto:
$6.75B
1 W Prestazione:
+2.27%
1M Prestazione:
-12.78%
6M Prestazione:
-23.69%
1 anno Prestazione:
+11.94%
Intervallo 1D:
$444.41
$454.45
Intervallo di 1 settimana:
$435.27
$455.00
Portata 52W:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | DZ Bank | Buy |
| 2025-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-12-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Downgrade | UBS | Buy → Neutral |
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Did Thermo Fisher’s AI-Focused Investor Day and Clario Deal Just Redefine TMO’s Investment Narrative? - simplywall.st
Thermo Fisher (TMO) director gets 499-share award, 80 withheld for tax - Stock Titan
Director at Thermo Fisher (NYSE: TMO) granted new shares - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share stock award - Stock Titan
Thermo Fisher (NYSE: TMO) director receives 499-share equity grant - Stock Titan
Thermo Fisher (TMO) director receives 499-share stock grant, now holds 2,602 - Stock Titan
Thermo Fisher (TMO) director Tyler Jacks receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) awarded 499 common shares - Stock Titan
Thermo Fisher (TMO) director Ruby R. Chandy receives 499-share stock grant - Stock Titan
Director at Thermo Fisher (NYSE: TMO) receives 499-share stock grant - Stock Titan
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
What Thermo Fisher CEO Said at Investor Day That the Market Is Still Processing - TIKR.com
What Thermo Fisher Scientific (TMO)'s New Gothenburg Lab Expansion Means For Shareholders - Yahoo Finance
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County - PA Department of Community & Economic Development (.gov)
Automated Microbiology Market to Reach USD 13.50 Billion by 2033 - openPR.com
Thermo Fisher Scientific’s SWOT analysis: stock navigates growth amid strategic shifts - Investing.com
High-Throughput Screening (HTS) Market Research Report to 2032 - openPR.com
Thermo Fisher Scientific Announces Quarterly Dividend - The National Law Review
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Declares Consistent Dividend of $0.47 Per Share - GuruFocus
TD Cowen Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating - Moomoo
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day - BioSpace
Press Release: Thermo Fisher Scientific Announces Quarterly Dividend - Moomoo
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 a Share, Payable July 15 to Shareholders of Record on June 15 - marketscreener.com
Thermo Fisher Scientific Inc Investor Day Transcript - GuruFocus
Thermo Fisher Scientific Inc Annual Shareholders Meeting Transcript - GuruFocus
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation - PharmiWeb.com
Thermo Fisher (TMO) Showcases Growth Potential at Investor Day - GuruFocus
Thermo Fisher (TMO) Projects Steady Growth with Strategic Focus - GuruFocus
Thermo Fisher Scientific highlights industry leadership, growth outlook and long-term value creation at 2026 Investor Day - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term - Investing.com
Thermo Fisher Expects 7% Annual Organic Revenue Growth Over Long Term - marketscreener.com
Thermo Fisher targets 7% organic revenue growth long-term By Investing.com - Investing.com Canada
Thermo Fisher Scientific : 2026 Investor Day - marketscreener.com
Thermo Fisher targets a $255B science market as AI reshapes drug discovery - Stock Titan
TMO Technical Indicators, RSI, MACD & Moving Averages - techi.com
Thermo Fisher Scientific Inc. announces Quarterly dividend, payable on July 15, 2026 - marketscreener.com
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Stock Down 31% From Its 52-Week High Despite Raising Full-Year EPS Guidance. Here’s What Happened - TIKR.com
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - PR Newswire UK
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics - News-Medical
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - BioSpace
12% Of This Thermo Fisher Scientific Insider's Holdings Were Sold - Moomoo
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with Ne - PharmiWeb.com
Top Companies Driving Innovation In Specimen Bag Zip Closure Solutions - SNS Insider
Life Science Instrumentation Market Forecast Report - GlobeNewswire
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading - Yahoo Finance UK
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
12,952 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by North Dakota State Investment Board - MarketBeat
Do Wall Street Analysts Like Thermo Fisher Scientific Stock? - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Unlocking a 39.52% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.77%
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):